FTC Sues ‘Big 3’ Pharmaceutical Benefit Managers

Alden Abbott October 14, 2024

Truth on the Market View Original Source

• 
  Back
  to Top

My last post highlighted a July 2024 Federal Trade Commission (FTC) interim staff report that was critical of pharmaceutical benefit managers (PBMs)—so-called “middlemen” firms that specialize in negotiating with drugmakers for rebates on the list prices of drugs. I explained that the interim report’s analysis is at odds with economic research that delineates the substantial economic benefits of the PBM system.

This piece turns to an assessment of the lawsuit the FTC filed in September against the three major PBMs. The lawsuit is weak and economically problematic.

Read the full piece here.